Drug intelligence / Profile preview

erlotinib + docetaxel + pemetrexed

Development stage: Preclinical
Lead developer: Astellas Pharma
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination chemotherapy regimen consisting of erlotinib (an EGFR tyrosine kinase inhibitor), docetaxel (a taxane), and pemetrexed (an antifolate antineoplastic agent). While each drug has established efficacy in non-small cell lung cancer (NSCLC) treatment, the specific three-drug combination has limited clinical evidence. Erlotinib blocks EGFR signaling, docetaxel disrupts microtubule function, and pemetrexed inhibits folate-dependent enzymes necessary for DNA synthesis.

Targets

TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))GART (GAR transformylase)DHFR (Dihydrofolate reductase)EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on erlotinib + docetaxel + pemetrexed.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on erlotinib + docetaxel + pemetrexed.

Explore the full profile